The results from the ADAURA clinical study further emphasized the clinical use of osimertinib in resected EGFR-mutated NSCLC patients, revealing a 2-year PFS rate of 89% in the osimertinib group, compared with only 52% in the placebo group[24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.